Lysosomes & Degradation — Explain lysosomes and autophagy; relate to degradation and recycling - Cell Biology

SECTION 1

Historical Context & Motivation

The discovery of intracellular degradation pathways fundamentally changed how biologists think about cellular homeostasis. Before the mid-twentieth century, researchers understood that cells could synthesize complex macromolecules, but the mechanisms by which these molecules were systematically dismantled and their components reused remained mysterious. The question was straightforward yet profound: how does a cell dispose of damaged proteins, worn-out organelles, and ingested pathogens without destroying itself in the process? The answer emerged through a series of elegant biochemical and ultrastructural studies that revealed a dedicated organelle — the lysosome — and a tightly regulated self-eating pathway known as autophagy.

1949 • Subcellular Fractionation Begins

Christian de Duve and colleagues at the Catholic University of Louvain use differential centrifugation to separate liver cell homogenates. They notice that acid phosphatase activity is latent — released only when membrane-bound particles are disrupted — hinting at a sequestered lytic compartment.

1955 • Lysosomes Named and Characterized

De Duve formally coins the term lysosome (from Greek lysis, 'loosening,' and soma, 'body') and proposes that these organelles contain hydrolytic enzymes enclosed in a single membrane, thereby protecting the cytoplasm from uncontrolled digestion.

1963 • Autophagy First Described

De Duve also introduces the term autophagy to describe the process by which cytoplasmic components are sequestered within double-membrane vesicles and delivered to lysosomes for degradation, as observed in electron micrographs of hepatocytes.

1974 • Nobel Prize for Lysosome Discovery

Christian de Duve shares the Nobel Prize in Physiology or Medicine with Albert Claude and George Palade for contributions to the structural and functional organization of the cell, including the discovery of lysosomes and peroxisomes.

2016 • Nobel Prize for Autophagy Mechanisms

Yoshinori Ohsumi receives the Nobel Prize in Physiology or Medicine for his genetic dissection of autophagy in yeast, identifying the ATG (autophagy-related) genes and elucidating the molecular machinery governing autophagosome formation.

The central question that lysosome biology addresses is one of controlled destruction: how can a cell maintain a compartment loaded with more than 60 different hydrolases capable of degrading virtually every biological macromolecule, yet prevent those enzymes from destroying the cell itself? Understanding this question requires an appreciation of membrane integrity, pH regulation, enzyme targeting, and the sophisticated signaling networks that link nutrient sensing to autophagic flux. These topics form the foundation of this lesson.

SECTION 2

Core Principles & Definitions

Lysosomes function as the principal degradative compartment of eukaryotic cells. Their ability to break down proteins, lipids, carbohydrates, and nucleic acids into monomeric building blocks positions them at the intersection of catabolism and biosynthesis. Several foundational principles govern lysosomal biology and the autophagy pathway.

Acidic Lumen

Lysosomes maintain an internal pH of approximately 4.5–5.0 via the vacuolar H⁺-ATPase (V-ATPase), a proton pump that hydrolyzes ATP to transport H⁺ ions into the lumen. This acidic environment is optimal for the activity of resident acid hydrolases and serves as a protective mechanism: should lysosomal contents leak into the neutral cytoplasm, the enzymes become catalytically inactive.

Acid Hydrolases & Mannose-6-Phosphate Targeting

Lysosomal enzymes are synthesized in the rough ER, glycosylated, and tagged with a mannose-6-phosphate (M6P) residue in the cis-Golgi. M6P receptors in the trans-Golgi network (TGN) sort these enzymes into clathrin-coated vesicles destined for late endosomes, which mature into lysosomes.

Lysosomal Membrane Proteins (LAMPs)

The lysosomal membrane is studded with heavily glycosylated integral membrane proteins, primarily LAMP-1 and LAMP-2. The dense glycocalyx on the luminal face protects the membrane from digestion by the hydrolases it encloses. Transporters in the membrane export degradation products (amino acids, monosaccharides, fatty acids) back to the cytoplasm for reuse.

Autophagy — Macro, Micro, and CMA

Autophagy is broadly divided into three types. Macroautophagy involves de novo formation of a double-membrane autophagosome that engulfs cytoplasmic cargo. Microautophagy involves direct invagination of the lysosomal membrane. Chaperone-mediated autophagy (CMA) delivers unfolded substrate proteins bearing a KFERQ-like motif directly across the lysosomal membrane via LAMP-2A.

mTORC1 as Master Regulator

The mechanistic target of rapamycin complex 1 (mTORC1) assembles on the lysosomal surface when nutrients are abundant, phosphorylating ULK1 and TFEB to suppress autophagy. Under starvation or stress, mTORC1 dissociates, ULK1 activates autophagosome nucleation, and TFEB translocates to the nucleus to upregulate lysosomal biogenesis genes.

✦

KEY TAKEAWAY

Think of the lysosome as a cell's recycling center combined with a waste treatment plant. Just as a city recycling facility breaks down old electronics, plastics, and metals into raw materials that manufacturers can use again, the lysosome dismantles spent proteins, lipids, and organelles into amino acids, fatty acids, and sugars that the cell feeds back into biosynthetic pathways. The lysosomal membrane acts like the reinforced walls of the facility, preventing corrosive reagents from damaging the surrounding neighborhood (cytoplasm). Autophagy, then, is the scheduled pickup truck that collects worn-out cellular components and delivers them to the recycling center for processing.

SECTION 3

Lysosome Structure & Endolysosomal Pathway

Figure 1 illustrates the endolysosomal pathway. Acid hydrolases are synthesized in the rough ER, tagged with mannose-6-phosphate in the Golgi, and delivered to late endosomes that mature into lysosomes. Three major cargo delivery routes converge on the lysosome: receptor-mediated endocytosis from the plasma membrane, phagocytosis of pathogens, and autophagic engulfment of cytoplasmic material. After degradation, monomeric products (amino acids, sugars, fatty acids) are exported to the cytoplasm through specific membrane transporters.

The diagram emphasizes a critical architectural principle: the lysosome is not an isolated digestive sac but rather a convergence hub for multiple degradation pathways. Material arriving via endocytosis (extracellular macromolecules, receptor-ligand complexes), phagocytosis (bacteria, apoptotic cell debris), and autophagy (damaged organelles, aggregated proteins) all ultimately fuse with the lysosome for hydrolytic processing. The V-ATPase continuously pumps protons into the lumen, maintaining the acidic pH that is essential for hydrolase activity. Meanwhile, LAMP proteins form a protective glycocalyx that shields the limiting membrane from self-digestion.

SECTION 4

Molecular Mechanisms of Autophagy

Macroautophagy — typically referred to simply as autophagy — proceeds through a well-characterized series of molecular steps orchestrated by the ATG (autophagy-related) proteins. Yoshinori Ohsumi's genetic screens in Saccharomyces cerevisiae identified over 40 ATG genes, many of which have mammalian orthologs. The core pathway can be dissected into five stages: initiation, nucleation, elongation, fusion, and degradation/recycling.

Stage 1 — Initiation: ULK1 Complex Activation

Under nutrient-rich conditions, mTORC1 phosphorylates ULK1 (Unc-51-like kinase 1) at Ser757, preventing its activation. When cells experience amino acid deprivation, energy deficit (high AMP/ATP ratio detected by AMPK), or growth factor withdrawal, mTORC1 dissociates from the lysosomal surface, and ULK1 is dephosphorylated. AMPK simultaneously activates ULK1 by phosphorylating it at Ser317 and Ser777. The active ULK1 complex — comprising ULK1, ATG13, FIP200, and ATG101 — translocates to specialized ER subdomains called omegasomes, marked by the PI3P-binding protein DFCP1.

Stage 2 — Nucleation: Class III PI3K Complex

ULK1 phosphorylates and recruits the VPS34 complex (class III phosphatidylinositol 3-kinase), which includes Beclin 1, VPS15, and ATG14L. This complex generates phosphatidylinositol-3-phosphate (PI3P) on the phagophore membrane. PI3P serves as a docking site for WIPI proteins (WD-repeat protein interacting with phosphoinositides), which in turn recruit the ATG12–ATG5–ATG16L1 elongation complex.

Stage 3 — Elongation: Two Ubiquitin-Like Conjugation Systems

Autophagosome expansion relies on two ubiquitin-like conjugation cascades. In the first, ATG12 is conjugated to ATG5 through E1-like enzyme ATG7 and E2-like enzyme ATG10; the ATG12–ATG5 conjugate then associates with ATG16L1 to form a multimeric complex that functions as an E3-like ligase for the second pathway. In the second cascade, pro-LC3 is cleaved by ATG4 to yield LC3-I, which ATG7 and ATG3 then conjugate to phosphatidylethanolamine (PE), producing LC3-II. LC3-II is embedded in both the inner and outer membranes of the growing phagophore and is widely used as a molecular marker of autophagosomes.

Stage 4 — Fusion with Lysosomes

The sealed autophagosome is transported along microtubules toward perinuclear lysosomes. SNARE proteins (syntaxin 17, SNAP29, and VAMP8) mediate membrane fusion to form the autolysosome. Rab7 and the HOPS tethering complex coordinate the docking process. Upon fusion, the inner autophagosomal membrane and its enclosed cargo are exposed to lysosomal hydrolases.

Stage 5 — Degradation and Nutrient Recycling

Proteases, lipases, glycosidases, and nucleases within the autolysosome degrade the cargo into amino acids, fatty acids, monosaccharides, and nucleotides. These monomers are exported to the cytoplasm via specific lysosomal membrane transporters, including the amino acid transporter SLC38A9 and the sugar transporter Spinster. Recycled building blocks feed into anabolic pathways or are oxidized for ATP production, thereby sustaining cell survival during nutrient stress.

ℹ

Selective vs. Bulk Autophagy

Autophagy can be non-selective (bulk degradation during starvation) or selective, targeting specific cargo. Selective autophagy subtypes include mitophagy (damaged mitochondria, mediated by PINK1/Parkin), pexophagy (peroxisomes), aggrephagy (protein aggregates via p62/SQSTM1), and xenophagy (intracellular pathogens). Cargo receptors such as p62, NBR1, and OPTN bridge ubiquitinated substrates to LC3 on the autophagosome.

SECTION 5

Autophagy Pathway — Visual Breakdown

Figure 2 summarizes the five stages of macroautophagy from initiation through degradation, along with a reference table of selective autophagy subtypes and their cognate cargo receptors. Each stage is regulated by specific ATG protein complexes, and selective pathways use dedicated receptors to bridge ubiquitinated cargo to LC3 on the autophagosomal membrane.

A critical point illustrated in this figure is the distinction between bulk and selective autophagy. Under starvation conditions, the phagophore non-selectively engulfs large volumes of cytoplasm, providing the cell with an emergency nutrient supply. By contrast, selective autophagy pathways operate constitutively at basal levels, performing quality-control functions analogous to targeted protein degradation by the ubiquitin–proteasome system. The cargo receptor p62/SQSTM1 is particularly well characterized: it contains both a ubiquitin-associated (UBA) domain that binds polyubiquitinated substrates and an LC3-interacting region (LIR) that tethers the cargo to the autophagosome. Accumulation of p62 in cells is widely used as an index of impaired autophagic flux.

SECTION 6

Worked Example — Interpreting an Autophagy Flux Assay

One of the most common experimental approaches to studying autophagy involves monitoring LC3-II levels by Western blot under different conditions. This worked example walks through the logic of interpreting such data, a skill essential for reading the primary literature in cell biology.

Interpreting LC3-II and p62 Western Blot Data

1
Step 1 — Understand the Experimental Setup

A researcher cultures HeLa cells under four conditions: (A) complete medium (control), (B) starvation medium (EBSS, 4 hours), (C) starvation medium + chloroquine (CQ, a lysosomal pH inhibitor), and (D) complete medium + chloroquine. Western blots are probed for LC3-I, LC3-II, p62, and β-actin (loading control). The goal is to determine whether starvation induces autophagic flux.
2
Step 2 — Predict Expected LC3-II Levels

LC3-II is generated during autophagosome formation and degraded when autophagosomes fuse with lysosomes. A common pitfall is equating increased LC3-II with increased autophagy; an increase could instead reflect blocked degradation. Chloroquine raises lysosomal pH, preventing hydrolase activity and thus blocking LC3-II turnover. Condition B (starvation alone) should show a moderate increase in LC3-II if autophagy is induced and flux is active. Condition C (starvation + CQ) should show a much larger increase because LC3-II is produced at a high rate but not degraded.

If LC3-II in condition C > LC3-II in condition B, autophagic flux is confirmed.
3
Step 3 — Interpret p62 Levels

p62 is a selective autophagy receptor that is itself degraded inside autolysosomes. Under active autophagy (condition B), p62 levels should decrease relative to the control. Under conditions where lysosomal degradation is blocked (C and D), p62 should accumulate. A finding of decreased p62 in condition B is consistent with functional autophagic flux.

Decreased p62 under starvation = functional autophagic degradation.
4
Step 4 — Quantify Autophagic Flux

Autophagic flux can be semi-quantitatively assessed as the difference in LC3-II band intensity between the CQ-treated and untreated conditions within the same nutrient context. Let LC3-II_CQ+ and LC3-II_CQ− represent normalized LC3-II intensities with and without CQ. Then Flux = LC3-II_CQ+ − LC3-II_CQ−. Suppose for the starvation condition: LC3-II_CQ+ = 3.8 (arbitrary units, normalized to actin) and LC3-II_CQ− = 1.5. Then Flux = 3.8 − 1.5 = 2.3. For the fed condition: LC3-II_CQ+ = 1.8, LC3-II_CQ− = 0.8, Flux = 1.0.

Starvation flux (2.3) > basal flux (1.0), confirming that starvation approximately doubles autophagic throughput.
5
Step 5 — Draw Conclusions

The combined evidence — increased LC3-II under starvation, further accumulation of LC3-II when CQ blocks degradation, and decreased p62 under starvation — demonstrates that amino acid deprivation induces a bona fide increase in autophagic flux in HeLa cells. This is the gold-standard interpretation framework recommended by the Bhatt and Bhatt autophagy guidelines and the widely cited Klionsky et al. guidelines paper.

Conclusion: Starvation induces true autophagic flux, not merely autophagosome accumulation.

SECTION 7

Lysosomal Dysfunction & Disease

Given the central role of lysosomes in cellular degradation, it is unsurprising that defects in lysosomal function underlie a significant number of human diseases. These range from the classical lysosomal storage disorders (LSDs) — caused by loss-of-function mutations in specific acid hydrolases — to neurodegenerative diseases in which impaired autophagy leads to toxic protein accumulation.

Disease / Condition	Defective Component	Cellular Consequence
Tay-Sachs disease	Hexosaminidase A (β-subunit)	GM2 ganglioside accumulation in neurons → progressive neurodegeneration
Gaucher disease	Glucocerebrosidase (GBA1)	Glucocerebroside storage in macrophages → hepatosplenomegaly, bone disease
I-cell disease	GlcNAc-1-phosphotransferase (M6P tagging)	Hydrolases secreted extracellularly instead of reaching lysosomes → multiple substrate accumulation
Pompe disease	Acid α-glucosidase (GAA)	Glycogen accumulation in lysosomes → cardiomyopathy, muscle weakness
Parkinson disease	PINK1 / Parkin (mitophagy) or GBA1 variants	Impaired mitophagy → damaged mitochondria accumulation, α-synuclein aggregation
Alzheimer disease	Presenilin 1 (PS1) affects V-ATPase targeting	Impaired lysosomal acidification → defective Aβ clearance

Selected diseases associated with lysosomal or autophagic dysfunction

⚕️

CLINICAL PERSPECTIVE

Enzyme replacement therapy (ERT) has been a breakthrough for several LSDs — particularly Gaucher and Pompe disease. Recombinant hydrolases are administered intravenously and taken up by cells via M6P receptors. However, ERT cannot cross the blood-brain barrier efficiently, limiting its utility for neurological manifestations. Gene therapy and substrate reduction therapy represent emerging alternatives. From a broader perspective, pharmacological modulation of autophagy — using mTORC1 inhibitors such as rapamycin analogs (rapalogs) — is being explored as a therapeutic strategy for neurodegenerative diseases characterized by protein aggregation.

SECTION 8

Lysosomes as Signaling Platforms & Emerging Concepts

The classical view of the lysosome as a simple degradative bag has been dramatically revised over the past two decades. Lysosomes are now recognized as dynamic signaling hubs that integrate nutrient status, growth factor signaling, and stress responses. The discovery that mTORC1 is recruited to the lysosomal surface by the Ragulator–Rag GTPase complex placed the lysosome at the heart of cellular growth control. Amino acids sensed within the lysosomal lumen by SLC38A9 and the v-ATPase activate the Rag GTPases, which then recruit mTORC1 for activation by Rheb, itself regulated by growth factor signaling through TSC1/TSC2.

Feature	Classical View	Contemporary Understanding
Primary function	Terminal degradative compartment	Degradation hub + nutrient-sensing signaling platform
Positioning	Static perinuclear	Dynamic: perinuclear under starvation, peripheral under fed conditions; regulated by TFEB, Rab7, and kinesins
Biogenesis regulation	Constitutive, housekeeping	Transcriptionally regulated by TFEB/TFE3; responsive to stress, starvation, and infection
Calcium storage	Not considered	Major intracellular Ca²⁺ store; TRPML1 channel releases Ca²⁺ for calcineurin-TFEB signaling and membrane fusion
Membrane repair	Not recognized	Lysosomal membrane damage activates ESCRT-III repair machinery; extensive damage triggers lysophagy (autophagy of damaged lysosomes)

Evolution of the lysosome concept: classical vs. contemporary perspectives

One of the most exciting recent discoveries is the role of the transcription factor TFEB (transcription factor EB) as a master regulator of lysosomal biogenesis and autophagy. Under fed conditions, mTORC1 phosphorylates TFEB on the lysosomal surface, promoting its cytoplasmic retention via 14-3-3 protein binding. Upon starvation or lysosomal stress, TFEB is dephosphorylated by the phosphatase calcineurin (activated by TRPML1-mediated Ca²⁺ release) and translocates to the nucleus, where it upregulates the CLEAR (Coordinated Lysosomal Expression and Regulation) gene network — encompassing genes for lysosomal hydrolases, membrane proteins, V-ATPase subunits, and autophagy machinery. This feedforward loop enables cells to scale up their degradative capacity in response to demand, revealing a level of organelle biogenesis regulation that was scarcely imagined when lysosomes were first characterized.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why lysosomal enzymes would be largely inactive if they leaked into the cytoplasm. What specific property of the cytoplasmic environment provides this safeguard, and under what circumstances might this protection fail?

Show answer

Lysosomal hydrolases are acid hydrolases with pH optima near 4.5–5.0. The cytoplasmic pH is approximately 7.2, which is far above the optimal range for these enzymes, rendering them catalytically inactive or minimally active. This pH differential represents a critical safety mechanism: even if small amounts of hydrolase leak through the lysosomal membrane, they cannot efficiently degrade cytoplasmic substrates at neutral pH. However, this protection can fail during lysosomal membrane permeabilization (LMP), which may occur during extreme oxidative stress, after exposure to lysosomotropic agents, or during pathogen-mediated membrane damage. Extensive LMP can release cathepsins into the cytoplasm, and while individual cathepsins such as cathepsin B retain some activity at neutral pH, the major consequence is activation of inflammasomes and cell death pathways rather than wholesale cytoplasmic digestion.

Question 2: BASIC CALCULATION

The lysosomal lumen pH is approximately 4.8, while the cytoplasmic pH is approximately 7.2. Calculate the ratio of H⁺ concentration inside the lysosome to that in the cytoplasm. Recall that [H⁺] = 10⁻ᵖᴴ.

Show answer

Using the equation [H⁺] = 10⁻ᵖᴴ, we find [H⁺]_lysosome = 10⁻⁴·⁸ ≈ 1.58 × 10⁻⁵ M and [H⁺]_cytoplasm = 10⁻⁷·² ≈ 6.31 × 10⁻⁸ M. The ratio is (1.58 × 10⁻⁵) / (6.31 × 10⁻⁸) ≈ 251. Thus, the H⁺ concentration inside the lysosome is roughly 250-fold higher than in the cytoplasm. This difference of about 2.4 pH units represents the steep proton gradient maintained by the V-ATPase, which must work continuously against this concentration gradient, consuming ATP in the process. This calculation underscores why inhibiting the V-ATPase (e.g., with bafilomycin A1) rapidly neutralizes lysosomal pH and blocks degradation.

Question 3: INTERMEDIATE

A researcher observes increased LC3-II levels in drug-treated cells compared to control cells. Design an experiment to determine whether the drug stimulates autophagosome formation or blocks autophagosome–lysosome fusion. Describe the expected outcomes for each scenario.

Show answer

The researcher should perform a flux assay by adding a lysosomal inhibitor such as chloroquine (CQ) or bafilomycin A1 (BafA1) in addition to the drug. If the drug stimulates autophagosome formation (increased flux), then drug + CQ should show even higher LC3-II levels than drug alone, because the accelerated production of autophagosomes is now coupled with blocked degradation. If the drug blocks autophagosome–lysosome fusion (impaired flux), then adding CQ should not further increase LC3-II levels beyond the drug-alone condition, because LC3-II is already not being degraded. Additionally, the researcher could monitor p62 levels: if the drug increases flux, p62 should decrease; if it blocks flux, p62 should accumulate. Immunofluorescence microscopy showing co-localization (or lack thereof) of LC3 puncta with LAMP-1 would provide complementary visual evidence of fusion competence.

Question 4: APPLIED

In I-cell disease (mucolipidosis II), the enzyme GlcNAc-1-phosphotransferase is deficient, preventing addition of the mannose-6-phosphate tag to lysosomal hydrolases. Predict the cellular and clinical consequences of this deficiency. Which cell types might be least affected, and why?

Show answer

Without M6P tagging, newly synthesized lysosomal hydrolases cannot be recognized by M6P receptors in the trans-Golgi network. Instead of being sorted into clathrin-coated vesicles destined for late endosomes, the hydrolases follow the default secretory pathway and are released extracellularly. Intracellularly, lysosomes become engorged with undigested substrates (hence the name 'inclusion cell' disease), leading to cellular dysfunction particularly in fibroblasts and mesenchymal cells. Clinically, patients exhibit skeletal abnormalities, coarse facial features, psychomotor retardation, and organomegaly. Hepatocytes are relatively spared because they possess an alternative, M6P-independent pathway for lysosomal enzyme targeting involving the lysosomal integral membrane protein LIMP-2 and direct secretion-recapture mechanisms that allow them to internalize secreted hydrolases from the extracellular space. This differential vulnerability explains why liver function is better preserved than connective tissue integrity in I-cell disease.

Question 5: CRITICAL THINKING

Some cancer cells upregulate autophagy to survive nutrient-poor tumor microenvironments, while other studies show that autophagy suppresses tumorigenesis by clearing damaged organelles and oncogenic proteins. Discuss this paradox: under what circumstances might therapeutic inhibition of autophagy benefit cancer patients, and when might therapeutic activation be preferable? Consider the tumor stage and genetic context in your answer.

Show answer

This is the dual-role paradox of autophagy in cancer. In pre-malignant cells and early tumorigenesis, autophagy functions as a tumor-suppressive mechanism by removing damaged mitochondria (which produce reactive oxygen species that cause mutagenic DNA damage), clearing misfolded and aggregated proteins, and maintaining genomic stability. Loss of autophagy genes such as BECN1 (Beclin 1) is associated with increased tumor incidence in mouse models, and monoallelic deletion of BECN1 is found in breast, ovarian, and prostate cancers. In this context, therapeutic activation of autophagy (e.g., via mTOR inhibitors) could help prevent malignant transformation. However, in established tumors — particularly those driven by oncogenes such as KRAS or those growing in hypoxic, nutrient-depleted microenvironments — autophagy becomes a survival mechanism. Cancer cells rely on autophagic recycling to sustain amino acid pools, maintain mitochondrial function, and resist chemotherapy-induced stress. In this scenario, therapeutic inhibition of autophagy using hydroxychloroquine (which raises lysosomal pH) combined with standard chemotherapy can enhance tumor cell killing. Clinical trials combining hydroxychloroquine with chemotherapy or targeted therapy have shown promise in pancreatic cancer, where KRAS-driven tumors are particularly autophagy-dependent. Thus, the optimal strategy depends on tumor stage (prevention vs. treatment of established disease), genetic context (p53 status, RAS mutations), and metabolic dependency.

SUMMARY

Lesson Summary

Summary

Lysosomes are membrane-bound organelles containing over 60 acid hydrolases that function optimally at pH 4.5–5.0, maintained by the V-ATPase proton pump. Lysosomal enzymes are targeted via the mannose-6-phosphate pathway from the Golgi, and the lysosomal membrane is protected by heavily glycosylated LAMP proteins. Lysosomes serve as the convergence point for endocytic, phagocytic, and autophagic pathways, degrading macromolecules into monomeric building blocks that are recycled to the cytoplasm.

Macroautophagy proceeds through five stages — initiation (ULK1), nucleation (VPS34/Beclin 1), elongation (LC3 lipidation), fusion (SNAREs), and degradation — regulated by the mTORC1–AMPK signaling axis. Selective autophagy subtypes (mitophagy, aggrephagy, xenophagy) use specific cargo receptors such as p62/SQSTM1 to link ubiquitinated substrates to LC3. Dysfunction in lysosomal enzymes causes lysosomal storage disorders, while impaired autophagy is implicated in neurodegenerative diseases. Contemporary research has recast the lysosome as a nutrient-sensing signaling platform whose biogenesis is transcriptionally controlled by TFEB.